CTRI/2021/07/034924 [Registered on: 16/07/2021] Trial Registered Prospectively
Last Modified On:
08/05/2025
Post Graduate Thesis
No
Type of Trial
PMS
Type of Study
Drug Other (Specify) [Investigational drug :Topical Solution]
Study Design
Single Arm Study
Public Title of Study
Active Post-Marketing Surveillance of Diperoxochloric Acid [DPOCL] in patients with diabetic neuropathic ulcers of skin and subcutaneous tissue
Scientific Title of Study
A Prospective, Open-Label, Multi-centered, Non-Randomized, Non-Comparative Active Post-Marketing Surveillance to test the safety and efficacy of Diperoxochloric Acid [DPOCL] topical solution in Subjects with diabetic neuropathic ulcers of skin and subcutaneous tissue
Trial Acronym
Secondary IDs if Any
Secondary ID
Identifier
Active PMS- Protocol no. 082-20 dated 01.01.2020
Protocol Number
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
Name
Dr Mukund Zarapkar
Designation
Vice President - Clinical
Affiliation
LifeSan Clinical Research, division of Centaur Pharmaceuticals Pvt. Ltd.
Address
5th and 6th floor, Centaur House, Near Hotel Grand Hyatt, Santacruz East, Mumbai 400055, India
Mumbai (Suburban) MAHARASHTRA 400055 India
Phone
91-22-66499154
Fax
91-22-66499108
Email
drzarapkar@lifesan.in
Details of Contact Person Scientific Query
Name
Dr Mayuresh Kiran
Designation
Vice President - Medical services and Pharmacovigilance
Affiliation
Centaur Pharmaceuticals Pvt. Ltd. India
Address
5th and 6th floor, Centaur House, Near Hotel Grand Hyatt, Vakola, Santacruz East, Mumbai 400055, India
Mumbai (Suburban) MAHARASHTRA 400055 India
Phone
91-22-66499156
Fax
91-22-66499108
Email
drmayuresh@centaurlab.com
Details of Contact Person Public Query
Name
Dr Mukund Zarapkar
Designation
Vice President - Clinical
Affiliation
LifeSan Clinical Research, division of Centaur Pharmaceuticals Pvt. Ltd.
Address
5th and 6th floor, Centaur House, Near Hotel Grand Hyatt, Santacruz East, Mumbai 400055, India
Mumbai (Suburban) MAHARASHTRA 400055 India
Phone
91-22-66499154
Fax
91-22-66499108
Email
drzarapkar@lifesan.in
Source of Monetary or Material Support
Centaur Pharmaceuticals Pvt. Ltd. India
Address: Centaur house, near Grand hyatt hotel, Vakola, Santacruz East Mumbai 400055
Primary Sponsor
Name
Centaur Pharmaceuticals Pvt Ltd
Address
CENTAUR HOUSE, Opp. Grand Hyatt, Vakola, Santacruz - East, Mumbai - 400 055, India.
Tel. No.91-22-66499100
Fax 91-22-66499108
Grant Gov. Medical College& Sir J.J. group Hospital
Grant Gov. Medical College &Sir J.J. group hospital,496,Mathar Pakhadi Rd, Rly Colony, Railway Colony,Byculla, Mumbai,Maharashtra 400010 Mumbai MAHARASHTRA
9820218198
gdbakhshi@yahoo.com
Dr Govinda Raju Chintada
Great Eastern Medical School & Hospital
Ground Floor, Room No. 02, Main Block, Great Eastern Medical School and Hospital, Ragolu, Srikakulam, Andhra Pradesh Srikakulam ANDHRA PRADESH
9393932828
drgovindrajugems@gmail.com
Dr Abhishek Kumar Gond
GSVM medical college, Kanpur
Department of surgery, Swaroop Nagar, Kanpur Nagar, Uttar Pradesh-208002,India Kanpur Nagar UTTAR PRADESH
Mysore Medical college and research institute, Irwin Road, next to Railway Staion, Mysuru, Karnataka 570001 Mysore KARNATAKA
9448089500
drdinesh70@gmail.com
Dr Shivashankara K N
Kasturba Hospital, Manipal
Department of Surgery,Post box no. 7, Kasturba hospital, Manipal,576104, Karnataka, India Udupi KARNATAKA
9448623861 918202571934 drshishakn@vahoo.co.in
Dr Shibani Kumar Sen
KIDS Hospital (Kanungo Institute of diabetes specialty) Bhubaneshwar
1120, Dumduma, Bhubaneswar, Odisha 751019, India
9437375562
drsksen1@gmail.com
Dr Kushagra Gaurav
King Georges medical university U.P.
King Georges medical university U.P., Shah Mina Rd, Chowk, Lucknow, Uttar Pradesh 226003 Lucknow UTTAR PRADESH
8932985717
kushagra_gaurav@yahoo.co.in
Dr Rajesh Shankar Powar
KLES Dr. Prabhakar Kore Hospital
Department of Plastic Surgery, KLES Dr. Prabhakar Kore hospital & MRC, NH Service Road, Basava Circle, Chikodi, Nehru Nagar, Belgaum, Karnataka 590010 Belgaum KARNATAKA
919448113864 918312493777 drrajeshpowar@gmail.com
Dr Dhritiman Maitra
Medical College & Hospital, Kolkata
Department of general surgery, 88, College St, Calcutta Medical College, College Square, Kolkata, West Bengal 700073 Kolkata WEST BENGAL
Adhar Institutional Ethics committee for Dr. Sandeep Suri
Approved
ASRAMS BHR Ethics Committee for Dr. K Suhas
Approved
Ethics Committee GSVM medical college Kanpur for Dr. Abhishek Kumar Gond
Approved
Ethics committee of Bangalore medical college and research institute for Dr. Harindranath and Dr. K.T. Ramesh
Approved
Ethics Committee on Human Research for Dr.Vishnu M.
Approved
GGMC and Sir JJH, Institutional Ethics committeefor Dr. Girish Bakhshi
Approved
Hycare Institutional Ethics Committee for Dr. J. Pandiaraja
Approved
Hycare Institutional Ethics Committee for Dr. Rajesh Kesavan
Approved
IEC Vincare Hospital
Approved
Institutional Ethics Committee of AIIMS, Bhubaneswar for Dr. Mainak Mallik
Approved
Institutional Ethics Committee (IEC)-I Seth GS medical college and KEM hospital for Dr. Shilpa Rao
Approved
Institutional Ethics Committee Great Eastern Medical School & Hospital for Dr Govinda Raju Chintada
Approved
Institutional Ethics Committee of All India Institute of Medical Sciences Bhubaneswar for Dr. Sanjay Kumar Giri
Approved
Institutional Ethics Committee of NKP Salve Institute of Medical Sciences & Research Centre and Lata Mangeshkar Hospital for Dr. Shriniket Sawarkar
Approved
Institutional Ethics Committee of SRI Ramachandra institute of higher education and research for Dr. Raja Senthil
Approved
Institutional Ethics committee of SRM medical college hospital and research centre for Dr. M. Reegan Jose
Approved
Institutional Ethics Committee of Subharti Medical College & Hospital for Dr. Dhanesh Kumar
Approved
Institutional Ethics Committee Sanjay Gandhi Post Graduate Institute of Medical Sciences for Dr. Gyan Chand
Approved
Institutional Ethics Committee, BLDE, Vijayapura for Dr. Aravind V. Patil
Approved
Institutional Ethics Committee, Medical college of Kolkata for Dr. Dhritiman Maitra
Approved
Institutional ethics committee, Mysore medical college and research Institute for Dr. Dinesh H. N.
Approved
Integrity Ethics Committee for Dr. Sanjay Kucheria
Approved
KIDS ethics committee for Dr. S.K.Sen
Approved
King Georges Medical University U.P., Institutional Ethics Committee for Dr. Kushagra Gaurav
Approved
KLES J. N medical college for Dr. Rajesh Powar
Approved
MAHE Ethics Committee for Dr. S. S. Prasad
Approved
MGMs Ethics Committee Research on Human Subject for Dr. Tejinder Singh Chhabda
Approved
Moraya Institutional Ethics Committee for Dr. Virendra Athavale
Approved
SDM college of medical Sciences & Hospital for Dr. B. Srinivas Pai
Approved
Sri Guru Ram Das Institute of Medical Sciences & Research Sri Amritsar Institutional Ethics Committee for Dr. Rana Ranjit Singh Sohal
Approved
Suraksha Ethics Committee for Dr. Hemant Patil
Approved
Suraksha Ethics Committee for Dr. Tushar Rege
Approved
Swasthyam Ethics Committee for Dr. Rohit Gupta
Approved
Telerad RxDx Healthcare Pvt. Ltd For Dr. Sanjay Sharma
Approved
V3 Healthcare Private Limited IEC for Dr. P. K. Sachan
Approved
V3 Healthcare Private Limited IEC for Dr. Sanjay Juyal
Approved
Yashodhan Hospital, Jalgaon for Dr. Milind Chaudhari
Approved
Regulatory Clearance Status from DCGI
Status
Approved/Obtained
Health Condition / Problems Studied
Health Type
Condition
Patients
(1) ICD-10 Condition: E114||Type 2 diabetes mellitus with neurological complications,
Intervention / Comparator Agent
Type
Name
Details
Intervention
Diperoxochloric Acid [DPOCL] topical solution
This pack contains two bottles:
Bottle A: Diperoxochloric acid concentrate
(each ml of solution contains: Diperoxochloric Acid Concentrate - 1.16 mg)
Bottle B: Sterile Sodium Chloride Solution BP - 0.9% w/v
Prior to application bottle A will be mixed with bottle B and Reconstituted Solution (Bottle A + Bottle B) would be prepared in the bottle B.
The dosage of reconstituted solution is 3.5 mL to be applied on the inner gauze admeasuring 5 × 5 cm prior to application on the intended diabetic foot ulcer
Total duration of the clinical trial will be of 70 days. At day 0, patient/ patients guardian will be informed about the Active Post-Marketing Surveillance.
On visits 0 and 1, one investigational product will be provided to the subject whereas on visits 2, 3, 4 and 5 two investigational products will be provided to the subject by the investigator at no cost.
All the patients will be asked to revisit the clinical trial center for efficacy and safety assessment at day 7, day 14, day 28, day 42, day 56 and day 70 along with their lab reports of day 0 and day 70.
Comparator Agent
Not applicable
Not applicable
Inclusion Criteria
Age From
18.00 Year(s)
Age To
80.00 Year(s)
Gender
Both
Details
1.Subjects diagnosed with either Type I or II - diabetes mellitus.
2.Subjects having random blood sugar [RBG] of < 250 mg/dL on standard anti-diabetic treatment.
3.Subjects having glycosylated hemoglobin of less than 7%.
4.Age: >18 years of either gender (Male/ Female).
5.Ulcers with wound surface area measured by greatest length, greatest width between 1 cm2 and 25 cm2 post-debridement on the day 0.
6.At least 1 but not more than 3 full thickness [i.e. extending into subcutaneous tissue or beyond] ulcer at foot or below malleolus with at least 4 weeks history and graded as stage I-A, II-A or I-B on University of Texas wound classification system
7.Subjects with Ankle-Brachial Pressure Index [ABPI] > 0.7
8.All the subjects willing to voluntarily participate in the clinical trial and signing on duly filled Informed Consent Form.
ExclusionCriteria
Details
1.Subjects with more than 3 ulcers.
2.Subjects with ulcers measuring wound surface area more than 25 cm2.
3.Ulcers caused by venous or arterial insufficiency or electrical or chemical burns.
4.Ulcers caused by surgery and especially amputation surgery.
5.Ulcers showing presence of necrosis, purulence or sinus tracts that cannot be removed by debridement.
6.Subjects having history of active Charcoat’s foot of the study foot within 6 months of screening.
7.Subjects having severe or poorly controlled diabetes mellitus with severe hyperglycemia (RBG > 250 mg/dL).
8.Subjects having glycosylated hemoglobin of more than 12%.
9.Subjects having progressive weight loss.
10.Treatment with corticosteroids, immunosuppressive or chemotherapeutic agents, radiotherapy.
11.Other diseases, which can alter the course of diabetic foot ulcer such as connective tissue disease, renal failure (serum creatinine > 3mg /dL) liver failure, malignancy.
12.Revascularization surgery performed <8 weeks before entry in the study.
13.Pregnant or nursing mothers.
14.Mentally or neurologically disabled subjects that are considered not fit to approve their participation in the study.
15.Subjects with Ankle-Brachial Pressure Index [ABPI] < 0.7.
Method of Generating Random Sequence
Not Applicable
Method of Concealment
Not Applicable
Blinding/Masking
Open Label
Primary Outcome
Outcome
TimePoints
The primary objective of this study is to evaluate the safety of Diperoxochloric Acid [DPOCL] topical solution in patients with diabetic neuropathic ulcers of skin and subcutaneous tissue on the basis of AE/ SAE, clinical chemistry (safety lab) and complete physical examination.
at every visit that is week 1, week 2, week 3, week 4, week 6, week 8 and week 10
Secondary Outcome
Outcome
TimePoints
The secondary objective of this study is to evaluate the efficacy of Diperoxochloric Acid [DPOCL] topical solution in patients with diabetic neuropathic ulcers of skin and subcutaneous tissue.
at every visit that is week 1, week 2, week 3, week 4, week 6, week 8 and week 10
Target Sample Size
Total Sample Size="200" Sample Size from India="200" Final Enrollment numbers achieved (Total)= "319" Final Enrollment numbers achieved (India)="319"
Individual Participant Data (IPD) Sharing Statement
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
Brief Summary
Diperoxochloric Acid Topical solution is indicated for wound healing in diabetic neuropathy ulcer of skin and subcutaneous tissue.
Overview of the Study Design
It will be a Prospective, Open-Label, Multi-centered, Non-Randomized, Non-Comparative Active Post-Marketing Surveillance to test the safety and efficacy of Diperoxochloric Acid [DPOCL] topical solution in patients with diabetic neuropathic ulcers of skin and subcutaneous tissue. The study will be conducted at 20 centers, with number of patients not less than 200 and not more than 500.
Total duration of the clinical trial will be of 70 days. At day 0, patient/ patients guardian will be informed about the ‘’Active Post-Marketing Surveillance’’.
If the patient agrees and eligible as per inclusion and exclusion criteria, then his/ her sign will be taken on ICF and patient will be recruited.
On visits 0 and 1, one investigational product will be provided to the subject whereas on visits 2, 3, 4 and 5 two investigational products will be provided to the subject by the investigator at no cost.
All the patients will be asked to revisit the clinical trial center for efficacy and safety assessment at day 7, day 14, day 28, day 42, day 56 and day 70 along with their lab reports of day 0 and day 70.
For each visit, a grace period of ± 2 days will be given to patients and will not be considered as protocol deviation.
The primary objective of this study is to evaluate the safety of Diperoxochloric Acid [DPOCL] topical solution in patients with diabetic neuropathic ulcers of skin and subcutaneous tissue on the basis of AE/ SAE, clinical chemistry (safety lab) and complete physical examination.
Secondary Objective
The secondary objective of this study is to evaluate the efficacy of Diperoxochloric Acid [DPOCL] topical solution in patients with diabetic neuropathic ulcers of skin and subcutaneous tissue.
Dosage:
Before applying to the wound dressing, Diperoxochloric Acid concentrate (Bottle A) has to be ‘’reconstituted’’ by mixing the contents of bottle A into the contents of bottle B as per the instructions provided below.
Instructions for preparation of Diperoxochloric Acid Topical Solution “Reconstituted’’ solution and wound dressing.
Open ‘Bottle A’ and ‘Bottle B’.
Pour the contents of Bottle A into Bottle B.
Close the bottle B with bottle cap.
Discard the bottle A.
Mix the content by moving the bottle upside down for 5 times gently.
Application
Wash hands thoroughly before applying DPOCL topical solution.
Take out the dropper from the plastic bag (provided in the pack) and fill it on the bottle B.
Apply 3.5 mL of this solution with help of the dropper on the 5 x 5 cm dressing (inner gauze) to bring the dressing to earth moist conditions.
Do not touch dropper to the dressing or gauze.
Then apply this inner gauze on the wound.
Cover this inner gauze with outer gauze which will prevent the wound area from running dry.
Fix the gauze in position by rolling the bandage over the gauze and secure the ends by the microtape.
Daily remove the outer bandage and apply investigational product on inner bandage without removing the inner bandage form the wound.
Change the outer gauze daily and inner gauze on every alternate day.